Articles By Alyson Martin
Here’s What People Want the FDA to Know About CBD
The FDA has been collecting public comments since April to inform CBD product rules, and the window closes tomorrow. From state ag regulators to New York’s Bar Association, here are some highlights.
New York: Adult Use Cannabis Legalization Bill Officially Dead
On the road to the legislative session’s end, legalization at times seemed certain. But consensus among lawmakers, and support in the Senate, fell short.
FDA Extends Public Comment on Products Containing Cannabis
The agency, which will determine the future of the CBD industry, also provided an update on its information gathering. And yesterday, Canada’s health officials initiated a somewhat similar process.
New York’s Nail-Biter: Will “Zombie” Cannabis Legalization Bill Make It?
Today in Albany, the legislative session draws to a close.
Q&A: Do Competing Cannabis Interests Repackage Opioid Research?
A recent cannabis and opioid study highlighted that “corporate actors” with “deep pockets have substantial ability to promote congenial results, as suffering people are desperate for effective solutions.”
New York Lawmakers, Advocates Make Last-Ditch Cannabis Legalization Push
“The objections from members are varied, and for every one we satisfy, another objects,” Sen. Diane Savino told Cannabis Wire.
New York’s Cannabis Billboard Battle: SAM and Weedmaps take to the roads
Messages for and against legalization are popping up across the state as the deadline nears to pass an adult use bill.
New York Lawmakers Address the CBD Sprawl
Proposed legislation isn’t intended to bypass the FDA’s forthcoming national regulations. But with CBD products already on shelves, lawmakers can’t wait.
FDA Holds Historic Hearing on CBD to Shape the Future of the New Industry
"Across the United States, state and local regulators have been confronted with a huge onslaught of CBD.”
